Why the study?
Do intensive lipid-lowering treatments achieving very low LDL-C levels reduce cardiovascular events without increasing adverse events?
Do intensive lipid-lowering treatments achieving very low LDL-C levels reduce cardiovascular events without increasing adverse events?
Achieving very low LDL-C levels with intensive lipid-lowering therapy is safe and continues to reduce cardiovascular events.
Answers are grounded in this paper and cite their sources.
Supports aggressive LDL-C lowering in high-risk patients; extends meta-analytic confirmation of safety and benefit.
This meta-analysis indicates that very low LDL-C levels on intensive lipid-lowering treatments are not associated with any adverse event and maintain a persistent reduction of cardiovascular events.
No takes yet. Share an insight, caveat, or question.
Patti et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: